Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Beilei Wang

Showing results (131-140 of 173) with videos related to

Pageof 18
Sort By:
Advanced Healthcare Materials|November 1, 2013
Nanocomposite-strengthened dissolving microneedles for improved transdermal delivery to human skinLi Yan, Anthony P Raphael, Xiaoyue Zhu, et al.
Signal Transduction and Targeted Therapy|April 4, 2023
Discovery of IHMT-MST1-39 as a novel MST1 kinase inhibitor and AMPK activator for the treatment of diabetes mellitusJunjie Wang, Ziping Qi, Yun Wu, et al.
Journal of Medicinal Chemistry|January 21, 2016
Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid LeukemiaXiaofei Liang, Xiaochuan Liu, Beilei Wang, et al.
ACS Biomaterials Science & Engineering|November 29, 2021
Injectable Erythrocyte Gel Loaded with Bulleyaconitine A for the Treatment of Rheumatoid ArthritisHao Chen, Bo Tian, Xiyao Fang, et al.
European Journal of Pharmacology|May 10, 2023
Discovery of a highly potent pan-RAF inhibitor IHMT-RAF-128 for cancer treatmentAoli Wang, Juan Liu, Xixiang Li, et al.
European Journal of Medicinal Chemistry|September 19, 2020
Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutantsBeilei Wang, Wentao Zhang, Xuesong Liu, et al.
Journal of Medicinal Chemistry|October 19, 2021
Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell LymphomasBin Zhou, Xiaofei Liang, Husheng Mei, et al.
Journal of Medicinal Chemistry|August 29, 2022
Discovery of IHMT-MST1-58 as a Novel, Potent, and Selective MST1 Inhibitor for the Treatment of Type 1/2 DiabetesYun Wu, Ziping Qi, Beilei Wang, et al.
Journal of Medicinal Chemistry|November 12, 2020
Discovery of (<i>S</i>)-2-(1-(4-Amino-3-(3-fluoro-4-methoxyphenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)propyl)-3-cyclopropyl-5-fluoroquinazolin-4(3<i>H</i>)-one (IHMT-PI3Kδ-372) as a Potent and Selective PI3Kδ Inhibitor for the Treatment of Chronic Obstructive Pulmonary DiseaseFeng Li, Xiaofei Liang, Zongru Jiang, et al.
European Journal of Medicinal Chemistry|May 20, 2023
Structure-based discovery of IHMT-IDH1-053 as a potent irreversible IDH1 mutant selective inhibitorQianmao Liang, Beilei Wang, Fengming Zou, et al.
Pageof 18

Showing results (131-140 of 173) with videos related to

Sort By:
Pageof 18
Advanced Healthcare Materials|November 1, 2013
Nanocomposite-strengthened dissolving microneedles for improved transdermal delivery to human skinLi Yan, Anthony P Raphael, Xiaoyue Zhu, et al.
Signal Transduction and Targeted Therapy|April 4, 2023
Discovery of IHMT-MST1-39 as a novel MST1 kinase inhibitor and AMPK activator for the treatment of diabetes mellitusJunjie Wang, Ziping Qi, Yun Wu, et al.
Journal of Medicinal Chemistry|January 21, 2016
Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid LeukemiaXiaofei Liang, Xiaochuan Liu, Beilei Wang, et al.
ACS Biomaterials Science & Engineering|November 29, 2021
Injectable Erythrocyte Gel Loaded with Bulleyaconitine A for the Treatment of Rheumatoid ArthritisHao Chen, Bo Tian, Xiyao Fang, et al.
European Journal of Pharmacology|May 10, 2023
Discovery of a highly potent pan-RAF inhibitor IHMT-RAF-128 for cancer treatmentAoli Wang, Juan Liu, Xixiang Li, et al.
European Journal of Medicinal Chemistry|September 19, 2020
Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutantsBeilei Wang, Wentao Zhang, Xuesong Liu, et al.
Journal of Medicinal Chemistry|October 19, 2021
Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell LymphomasBin Zhou, Xiaofei Liang, Husheng Mei, et al.
Journal of Medicinal Chemistry|August 29, 2022
Discovery of IHMT-MST1-58 as a Novel, Potent, and Selective MST1 Inhibitor for the Treatment of Type 1/2 DiabetesYun Wu, Ziping Qi, Beilei Wang, et al.
Journal of Medicinal Chemistry|November 12, 2020
Discovery of (<i>S</i>)-2-(1-(4-Amino-3-(3-fluoro-4-methoxyphenyl)-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidin-1-yl)propyl)-3-cyclopropyl-5-fluoroquinazolin-4(3<i>H</i>)-one (IHMT-PI3Kδ-372) as a Potent and Selective PI3Kδ Inhibitor for the Treatment of Chronic Obstructive Pulmonary DiseaseFeng Li, Xiaofei Liang, Zongru Jiang, et al.
European Journal of Medicinal Chemistry|May 20, 2023
Structure-based discovery of IHMT-IDH1-053 as a potent irreversible IDH1 mutant selective inhibitorQianmao Liang, Beilei Wang, Fengming Zou, et al.
Pageof 18